Skip to main navigation
Skip to search
Skip to main content
Sort by
Keyphrases
Antiangiogenic Therapy
100%
Non-invasive Assessment
100%
Combination Therapy
100%
Image-guided
100%
Paclitaxel
80%
Pazopanib
60%
Novel Image
40%
Treatment Response
40%
Tumor Microenvironment
40%
Multiple Cytokines
20%
Therapy Drugs
20%
Cytotoxic Components
20%
Advanced Renal Cell Carcinoma (aRCC)
20%
Subsequent Cancer
20%
Vascular Supply
20%
Early Detection
20%
Nanocarriers
20%
Chemotherapy
20%
Tumor Vasculature
20%
Cytokine Receptor
20%
Poor Prognosis
20%
HER2-negative Metastatic Breast Cancer
20%
Antiangiogenic Agents
20%
Functional Imaging
20%
Tyrosine Kinase Receptor
20%
Confounding Effect
20%
Systemic Toxicity
20%
MRI Monitoring
20%
Drug Delivery
20%
Multikinase Inhibitor
20%
Drug Delivery System
20%
Disease Progression
20%
Cancer Progression
20%
Drug Delivery Vehicle
20%
Mortality Rate
20%
Aggressive Breast Cancer
20%
Anti-vascular Endothelial Growth Factor (anti-VEGF)
20%
Metastatic Disease
20%
Clinical Trials
20%
Breast Cancer
20%
Public Health
20%
Low Systemic Toxicity
20%
Tumor Aggressiveness
20%
Imaging Techniques
20%
Small Molecule Inhibitors
20%
Multiple Tumors
20%
Humanized Antibody
20%
Imaging-guided Drug Delivery
20%
Tumor Subtype
20%
Non-invasive Detection
20%
Delivery Properties
20%
Orthotopic Breast Cancer Model
20%
Image-guided Delivery
20%
Clinical Benefit
20%
In Cancer
20%
Tumor Hypoxia
20%
Tumor Resistance
20%
Tumor
20%
Signaling Pathway
20%
Progression-free Survival
20%
Molecular Imaging
20%
Oral Formulation
20%
Monoclonal Antibody
20%
Antiangiogenic
20%
Bevacizumab
20%
Tumor Detection
20%
Treatment Outcome
20%
Recurring
20%
Tumor Invasiveness
20%
Pharmacology, Toxicology and Pharmaceutical Science
Combination Therapy
100%
Antiangiogenic Therapy
100%
Neoplasm
66%
Paclitaxel
66%
Pazopanib
50%
Breast Cancer
50%
Tumor Microenvironment
33%
Mortality Rate
16%
Hypoxia
16%
Tyrosine Kinase Receptor
16%
Metastatic Breast Cancer
16%
Multiple Cancer
16%
Cytokine Receptor
16%
Nanocarrier
16%
Disease Exacerbation
16%
Tumor Resistance
16%
Malignant Neoplasm
16%
Bevacizumab
16%
Cancer Model
16%
Cancer Growth
16%
Drug Delivery System
16%
Progression Free Survival
16%
Clinical Trial
16%
Tumor Vascularization
16%
Vasculotropin
16%
Angiogenesis Inhibitor
16%
Renal Cell Carcinoma
16%
Monoclonal Antibody
16%